Evidence map›Paper›PMID 36449121›Full record

ArticleMycopathologia2023

In Vitro Combination of Terbinafine with Ketoconazole Against Aspergillus Species with Terbinafine High MIC Values Isolated From Otomycosis.

Mohsen Nosratabadi, Amirreza Espahbodi, Mohammad Taghi Hedayati, Tahereh Shokohi, Hamid Badali, Majid Saeedi, Maryam Moazeni, Seyed Reza Aghili, Javad Javidnia, Leila Faeli and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Mycopathologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Correlation between MIC of econazole nitrate and clinical response in otomycosis.Frontiers in cellular and infection microbiology · 2026
    Article
  2. Formulation, characterization, andCurrent medical mycology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Mohsen NosratabadiDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran.
Amirreza EspahbodiStudent Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Mohammad Taghi HedayatiDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran.
Tahereh ShokohiDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran.
Hamid BadaliDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran.
Majid SaeediDepartment of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Maryam MoazeniDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran.
Seyed Reza AghiliDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran.
Javad JavidniaDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran.
Leila FaeliDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran.
Shaghayegh KhojastehDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran.
Behrad RoohiDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran.
Kiana AbbasiDepartment of Microbiology, Zanjan Branch, Islamic Azad University, Zanjan, Iran.
Mahdi AbastabarDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran. mabastabar@gmail.com.
Iman HaghaniDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran Province, Iran. imaan.haghani@gmail.com.ORCID http://orcid.org/0000-0001-9723-7618
Mazandaran University of Medical Sciences · IRIslamic Azad University of Zanjan · IRTexas Center for Infectious Disease · US

Funding

Invasive Fungi Research Center, Mazandaran University of Medical Sciences 8937
6 · The paper itself

Abstract

Otomycosis is a common mycotic infection of the external auditory canal, and Aspergillus species are one of the most frequent causative agents worldwide. The limited antifungal arsenal, the high toxicity and side effects of antifungal agents, and the growing resistance to the currently available antifungals underscore the need for new therapeutic strategies. The present study aimed to evaluate the combined in vitro efficacy of terbinafine and ketoconazole against Aspergillus species with terbinafine high MIC values isolated from patients with otomycosis.84 Aspergillus species with high MIC values to terbinafine (≥ 4 µg/ml), consisting of A. flavus, A. tubingensis, A. niger, and A. terreus, were included in this study. The checkerboard microdilution method evaluated the in vitro interactions using the CLSI reference technique. Synergistic effects were observed for 66.67% (56/84) of all isolates (FICI ranging from 0.19 to 0.5). However, the interactions of terbinafine and ketoconazole exhibited indifference in 33.33% (28/84) of the isolates, and no antagonism was observed for any combination. The interaction of terbinafine and ketoconazole showed synergistic activity against Aspergillus species with high MIC values, suggesting that this is an alternative and promising approach for treating otomycosis.

Indexed as

KetoconazoleOtomycosisAntifungal AgentsAspergillusHumansMicrobial Sensitivity TestsTerbinafineAntifungal AgentsKetoconazoleTerbinafineAspergillus speciesCombinationKetoconazoleOtomycosisTerbinafine

Identifiers

PMID36449121
OpenAlexW4310466269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.